42 results about "Lipid vesicle" patented technology

The invention relates to the technical field of biomedical materials, in particular to a mitochondrial transplantation treatment system and application thereof. The mitochondrial transplantation treatment system provided by the invention comprises mitochondria obtained by separation and a transfer vector. Wherein the mitochondria transplantation treatment system is obtained by assembling the mitochondria and the transfer vector, and the transfer vector comprises at least one of artificial lipid vesicles, vesicles derived from cell membranes and exosomes. The preparation process of the mitochondrial transplantation treatment system is simple, healthy mitochondria can be efficiently and rapidly transferred into cells or tissues at the same time, and the mitochondrial function of damaged mitochondrial cells is repaired. The mitochondrial transplantation treatment system has the potential of treating related diseases caused by mitochondrial dysfunction.

The invention relates to the technical field of biology, and particularly discloses an acoustic fluid device and a method for controlling fusion of lipid vesicles through the acoustic fluid device, the device comprises a glass chamber and piezoelectric ceramics attached to the bottom face of the glass chamber, the piezoelectric ceramics are used for generating ultrasonic waves, and the glass chamber serves as a reaction chamber for fusing the lipid vesicles. The method comprises the following steps: determining a lipid vesicle fusion type, and determining vibration frequency and vibration intensity of required ultrasonic waves according to the type; and the piezoelectric ceramics generate ultrasonic waves with required vibration frequency and vibration intensity to act on the glass chamber. According to the invention, the intensity of the sound stream can be randomly and dynamically adjusted, so that the ultrasonic pulse is utilized to induce the sound stream to control the fusion of the lipid vesicles in a non-invasive manner. The method has the advantages of no toxicity, no chemical reagent residue, simple device, no special requirements on the physical properties of the fluid medium and the lipid membrane, non-contact control, good universality, no requirements on the bioprotein receptor on the surface of the lipid membrane and the components of the lipid membrane, and good biocompatibility.

The invention provides a membrane-wrapped organelle-like system for directionally assembling membrane protein, which comprises a molecular framework and a closed lipid bilayer membrane wrapping the outer side of the molecular framework, the molecular framework is loaded with load molecules, the molecular framework directionally recombines the lipid bilayer membrane through a transmembrane region of the membrane protein, and the lipid bilayer membrane is loaded with the load molecules. The lipid bilayer membrane provides a barrier and protection for a molecular framework and loaded molecules, and the lipid bilayer membrane is provided with directional recognition molecules. According to the invention, a molecular framework wrapped by a lipid bilayer membrane is utilized, and a novel technology capable of simulating lipid vesicles of an organelle membrane framework is adopted, so that a brand-new directional delivery function on specific cells or specific organelles in the specific cells can be endowed. And oriented assembly of a membrane protein compound and effective loading of bioactive molecules are realized by using a process of chemically recombining the lipid bilayer membrane.

The present disclosure provides a method for introducing a target molecule into a lipid vesicle (for example, an extracellular vesicle). The present disclosure also provides a lipid vesicle (for example, an extracellular vesicle) produced using the method for introducing a target molecule into a lipid vesicle (for example, an extracellular vesicle). According to the present disclosure, a complex (a first complex) of a lipid (for example, an ionic lipid; particularly a liquid lipid composition) and a target molecule is fused with a lipid vesicle (for example, an extracellular vesicle) to form a complex (a second complex). The first complex and the second complex are suitable for the introduction of the target molecule into a cell, and the second complex is particularly suitable for the introduction of the target molecule into a cell. The target molecule may be a protein (for example, an antibody), a nucleic acid, or other compounds.

This application relates to a biphasic lipid vesicle pharmaceutical composition comprising a lipid bilayer comprising vesicle-forming lipids, an oil-in-water emulsion stabilized by one or more surfactants, one or more compounds, and one or more penetration enhancers. The one or more penetration enhancers include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or in combination with one or more penetration enhancers selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants, and combinations thereof. This application also relates to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer, the biphasic lipid vesicle comprising a vesicle-forming lipid, an oil-in-water emulsion stabilized by one or more polycationic surfactants, and one or more compounds.

The present disclosure relates to compositions comprising phospholipids, lipid vesicles, and / or liposomes, and methods of use thereof. In one aspect, the present disclosure relates to methods and compositions for delivery of, biologically active lipids to reduce microvascular dysfunction and infarct size during revascularization of the blocked artery in a mammalian subject.

The invention relates to the technical field of lipid vesicle preparation, and particularly discloses size and position controllable lipid vesicle preparation equipment and method.The equipment comprises a cavity, a microarray structure and an ultrasonic transducer which are arranged hierarchically; the cavity is used for being filled with a physiological buffer solution; the surface of the microarray structure is provided with micropores with set sizes and positions, and lipid membranes are arranged in the micropores; the ultrasonic transducer emits ultrasonic waves to the microarray structure, the ultrasonic waves induce an array acoustic flow field through the micropore array structure of the microarray structure, and lipid membranes in micropores form spherical lipid vesicles under the combined action of Reynolds stress and the array acoustic flow field. According to the method, lipid vesicle preparation equipment is used for generating an array acoustic flow field to prepare the spherical lipid vesicles. According to the invention, inhibition of sodium chloride in a physiological buffer solution on lipid membrane expansion is broken through, the spherical lipid vesicles with controllable positions and sizes are prepared, and the spherical lipid vesicles are suitable for various lipid membranes.

The disclosure includes systems comprising non-viral DNA vectors encapsulated in lipid vesicles that are designed to achieve sustained therapeutically relevant expression levels in blood plasma of therapeutic proteins, polypeptides, or peptides. The system can express antibodies or antigen-binding fragments at sustained and therapeutically relevant levels. The system can be administered to a subject via local or systemic routes such as intravenous (IV) or intramuscular (IM), and repeat dosing produces an additive effect. For local administration, localized expression can be achieved. Applications span treatments for various conditions, including infectious diseases, cancers, and inflammatory diseases.

Provided are defined culture media for culturing pluripotent stem cells in a suspension culture devoid of substrate adherence, the defined culture media comprising an effective amount of a protease inhibitor; a GSK3β inhibitor and at least one agent selected from the group consisting of a protease inhibitor and a WNT3A polypeptide; a WNT3A polypeptide and a stabilizing agent thereof with the proviso that said stabilizing agent is not a lipid vesicle; and / or a GSK3β inhibitor, with the proviso that the medium is devoid of an ERK1 / 2 inhibitor. Also provided are cell cultures and methods of suing same.

Provided herein are lipid vesicle-coated magnetic beads, and methods of making and using the same.

The cosmetic composition comprises a vesicle concentrate consisting of an aqueous solution of vegetable lipid vesicles or lipid vesicles of plant origin having walls containing phospholipids, phytosphingosine, phytosterols, β-phytosteryl sulfate and optionally other derivatives of phytosterols, and ceramides and / or pseudoceramides, for use in the formulation of cosmetic products for the care of the skin and hair, and for decorative purposes for the face, eyes, eyelashes, lips and body. The vesicle concentrate may also contain lysophospholipids, esters of phytosterols, fatty acids, moisturizers, emollients, active lipophilic molecules, active hydrophilic molecules, thickeners and film-forming molecules. A cosmetic product comprises the vesicle concentrate cosmetic composition and other cosmetically acceptable ingredients.

The present invention provides methods of introducing a molecule of interest into a lipid vesicle, such as an extracellular vesicle. The present invention provides lipid vesicles (e.g., extracellular vesicles) obtained using a method for introducing a molecule of interest into lipid vesicles (e.g., extracellular vesicles). According to the present invention, a complex of a lipid (e.g., an ionic lipid, in particular a liquid lipid composition) and a molecule of interest (a first complex) is fused with a lipid vesicle (e.g., an extracellular vesicle) to form a complex (a second complex). The first complex and the second complex are suitable for introducing a target molecule into a cell, and the second complex is particularly suitable for introducing a target molecule into a cell. The target molecule may be a protein (e.g., an antibody), a nucleic acid, or other compound.

The application belongs to the technical field of medicine, and particularly relates to an anti-HPV earthworm extract delivery body gel and a preparation method and application thereof. The preparation method comprises the following steps: stirring and hydrating earthworm extract and a lipid layer to obtain lipid vesicles, then performing inflation, ultrasonic treatment and extrusion to obtain earthworm extract delivery bodies, and finally adding a carbomer after adjusting pH and uniformly mixing to obtain the anti-HPV earthworm extract delivery body gel. The application improves the inhibitory effect on HPV viruses by compounding the carbomer gel with the earthworm extract delivery body, can promote the shrinkage and death of cervical cancer cells, further improves the viscosity of the earthworm extract delivery body by combining the gel with the earthworm extract delivery body, improves the adhesion of the earthworm extract delivery body and the inner wall of the vagina, and thus improves the effect of preventing and treating HPV virus infection.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

The invention belongs to the technical field of plant genetic transformation, and discloses a liposome-mediated maize pollen transfection method. The method comprises the following steps: preparing a plasmid DNA solution and a mixed lipid vesicle SMV solution composed of lecithin and cationic lipid DOTMA, and mixing and incubating the plasmid DNA solution and the mixed lipid vesicle SMV solution according to a mass ratio to form an SMV-DNA compound transfection solution; collecting and pretreating fresh corn pollen, and co-incubating with the transfection solution at low temperature; after drying treatment, the pollen is directly used for pollinating female ears of receptor corn, and transgenic offspring seeds are obtained. According to the method, efficient delivery of exogenous DNA is realized by utilizing affinity and electrostatic interaction of liposome and pollen cell membranes, tissue culture is not needed, the method is independent of genotypes, the method is simple and convenient to operate and low in cost, the problem of somatic cell variation is effectively avoided, the transformation efficiency can reach about 1.4%, and an efficient and practical new technical approach is provided for corn genetic improvement.

Cosmetic composition containing a vesicular concentrate consisting of a water solution of vegetal or of vegetal origin lipid vesicles with walls comprising phospholipids, phytosfingosine, phytosterol, beta-phytosteryl sulfate and optionally other derivatives of phytosterol and ceramides and / or pseudoceramides used for preparing cosmetic products for skin and hair care and for decorating face, eyes, eyelashes, lips and body. Said vesicular concentrate can also comprise a lysophospholipid, ester of phytosterol, fatty acids, humectants, emollients, active lipophilic molecules, active hydrophilic molecules, thickening agents, and film-forming molecules. The cosmetic product contains said vesicular concentrate cosmetic composition and any other cosmetically acceptable ingredient.

A method of inhibiting or reducing the migratory ability of tumour cells in a subject is provided. The method involves administering to the subject a composition including Cripto-positive lipid vesicles, the Cripto protein being displayed on the surface of the Cripto-positive lipid vesicles.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

The invention relates to a composition for oral or topical human administration and a preparation method thereof. The present invention relates to pentacyclic triterpenoid compounds wherein said triterpenoid compounds are incorporated into lipid vesicles, preferably cream globules, surrounded by three layers of membranes. The triterpenoid is preferably betulinic acid, and / or betulinol, and / or lupenol, and / or oleanolic acid, and / or ursolic acid, most preferably betulinic acid. The incorporation of the triterpenoid compound into the milk fat globules or lipid vesicles at a high payload of at least 10 to at most 50 mg / ml is preferably accomplished with high energy emulsification techniques, most preferably ultrasound treatment. The composition is present as a liquid emulsion formulation in a preferred embodiment. In another preferred embodiment, the composition is a powder, which can be prepared from a liquid embodiment of the composition by, for example, spray drying or freeze drying techniques. The composition can be preferably used as a medicament, a food supplement or a nutraceuticals for the treatment or prevention of cancer, type 2 diabetes, obesity and cardiovascular diseases.

The invention discloses a method for preparing lipoid vesicles by a T-type mixing method, which specifically comprises the following steps: respectively dissolving a nonionic surfactant and cholesterol in absolute ethyl alcohol, and carrying out ultrasonic treatment to completely dissolve the nonionic surfactant and cholesterol; calculating the volume of the required solution according to the mass ratio of the nonionic surfactant to the cholesterol, and uniformly mixing the nonionic surfactant and the cholesterol to obtain a mixed solution; and the mixed solution and distilled water are simultaneously extruded through two inlets in the upper end of the T-shaped mixing pipe respectively, an organic phase is diluted into a water phase, and the polarity of the solvent is increased, so that the nonionic surfactant is aggregated and precipitated, and the lipoid vesicles are obtained at the output end. And ultrasonically reducing the particle size of the obtained lipoid vesicles through an ultrasonic cell crusher. And extruding by using a liposome extruder to obtain the lipoid vesicles with uniform particle size. The preparation method of the lipid vesicles is simple, the requirement on equipment is low, and conditions are easy to control; the obtained lipoid vesicles are small in particle size and good in monodispersity and stability, and can be used for preparing drug-loaded lipoid vesicles.

The invention discloses a method for preparing oleic acid lipid vesicles by using a magnetic stirrer, and relates to the technical field of biology, and the method comprises the following specific steps: S1, dissolving phosphatidylcholine in chloroform to obtain a phosphatidylcholine-chloroform solution, and carrying out vacuum drying on the phosphatidylcholine-chloroform solution in a glass bottle to obtain a lipid membrane; s2, adding a NaOH solution with the pH value of 8-9 into the glass bottle in which the lipid film is formed; s3, adding oleic acid into the mixed solution, heating, keeping constant temperature, and stirring by using a magnetic stirrer to obtain an oleic acid lipid vesicle solution. According to the method, the phosphatidylcholine is dissolved by using chloroform, then the alkaline solution and the oleic acid are added, and stirring is performed in a heating environment, so that the lipid vesicles can be prepared, the whole process is simple, the stirring time is short, and compared with an existing preparation method, the operation difficulty and the equipment cost are reduced.

The present invention provides a gas-containing multivesicular lipid nanoparticle and its application and preparation method. The lipid nanoparticle is a multivesicular nanoparticle composed of lipid vesicles with water as the inner cavity and lipid vesicles with gas as the inner cavity. The lipid nanoparticle can be used as a delivery system for nucleic acids or small molecule chemical drugs, and the corresponding vaccine or pharmaceutical composition is prepared by rapidly mixing the raw materials under the conditions of ultrasound and surfactant. While delivering nucleic acids or small molecule chemical drugs, the lipid nanoparticle can also provide an oxygen-rich or hydrogen-rich environment with positive biological effects, thereby improving the delivery efficiency of nucleic acids or small molecule chemical drugs. In addition, applying ultrasound in vitro can achieve directional explosion of gas-containing vesicles, which is expected to further improve the bioavailability and targeting of nucleic acids or small molecule chemical drugs.

The present disclosure relates to the technical field of biomedical materials, and in particular, to a mitochondrial transplantation therapy system and use thereof. The mitochondrial transplantation therapy system provided by the present disclosure comprises: mitochondria obtained by isolation; and a transfer carrier. The mitochondrial transplantation therapy system is obtained by assembling the mitochondria and the transfer carrier. The transfer carrier comprises at least one of an artificial lipid vesicle, a vesicle derived from a cell membrane, and an exosome. The mitochondrial transplantation therapy system has a simple preparation process, and enables efficient and rapid delivery of healthy mitochondria into cells or tissues at the same time, thereby repairing the mitochondrial function of mitochondria-damaged cells. The mitochondrial transplantation therapy system has the potential to treat related diseases caused by mitochondrial dysfunction.

This invention discloses a method for modifying lipid vesicles with an amphiphilic polymer containing N-oxide teramine groups. The amphiphilic polymer is OPDEA-PCL. OPDEA-PCL is used to modify synthetic liposomes, yielding amphiphilic polymer-synthetic liposome nanoparticles. OPDEA-PCL is also used to modify natural exosomes, yielding amphiphilic polymer-exosome nanoparticles. The amphiphilic polymer-synthetic liposomes of this invention possess active liver and lung targeting functions. This invention, through the engineered modification of exosomes with OPDEA-PCL, accurately guides exosomes to the liver regions requiring treatment, thereby enhancing the repair effect of exosomes on liver ischemia-reperfusion injury.

The invention relates to nanoparticles, nano eye drops as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a nanoparticle. The nanoparticle is composed of a tyrosine kinase inhibitor and a carrier protein, the mass ratio of the tyrosine kinase inhibitor to the carrier protein is (2-4): 1. The tyrosine kinase inhibitor-loaded nanoparticles are prepared and creatively combined with the photosensitizer-loaded lipid vesicles to obtain the synergistic photodynamic-VEGF inhibition difunctional photoresponsive nano eye drops which are uniform in particle size, simple and feasible in preparation method and good in stability; the photosensitizer and tyrosine kinase inhibitor co-delivery hydrogel prepared by the method realizes efficient co-delivery of the photosensitizer and the tyrosine kinase inhibitor, has a laser response release behavior, can be detained in eye tissues for a long time, not only greatly improves the bioavailability of hydrophobic drugs, but also realizes the final curative effect of resisting ocular angiogenesis, and has potential clinical application value.

The invention relates to cartilage affinity cross-linked liposome nanoparticles and a preparation method and application thereof.The cross-linked liposome nanoparticles are composed of multiple layers of lipid vesicles and ligands, the ligands are covalently conjugated to the multiple layers of lipid vesicles to form the cross-linked liposome nanoparticles, the ligands are sulfydryl modified polypeptides, and the sulfydryl modified polypeptides are covalently conjugated to the multiple layers of lipid vesicles to form the cross-linked liposome nanoparticles. Protein molecules and / or hydrophobic small molecule drugs are encapsulated by the cross-linked liposome nanoparticles to obtain the multi-layer cross-linked liposome, and the cross-linked liposome has cartilage affinity, can be combined with cartilage for a long time to prolong the residence time by delivering the drugs to cartilage where arthritis occurs in articular cavities, and can be used for preparing the cartilage drug. The staying time of the multi-layer cross-linked liposome in the articular cavity is prolonged to 40 days or above, and the cross-linked liposome nano-particles are non-toxic by increasing the local drug concentration and have a better drug delivery effect and excellent targeted binding performance.

The present invention is directed to formulations comprising a water-immiscible fluorocarbon solvent and at least one amphiphilic polymer, wherein the least one amphiphilic polymer is selected from a diblock co-polymer surfactant of formula A-B and a triblock co-polymer surfactant of formula B'-A'-B', wherein A and A' independently of each other represent a water-soluble polymer block having a weight average molecular weight in the range of 300 g / mol to 2000 g / mol, and B and B' represent independently of each other a perfluorinated polyether block having a weight average molecular weight in the range of 1500 g / mol to 7500 g / mol. Said formulations exhibit improved properties which render them particularly useful in droplet-based microfluidics applications, including the construction of lipid vesicles, cell encapsulation and monitoring, and droplet digital molecular biology.

The present application relates to a squeezing preparation method of the Caesalpinia minax lipid vesicle-like nanoparticles, comprising the following steps: mixing Caesalpinia minax and ultrapure water with a mass ratio of 1:6-1:10 to squeeze juice, then extruding the juice through a 100-200 mesh filter to obtain a Caesalpinia minax raw solution; then, gradient centrifuging the Caesalpinia minax raw solution to obtain a supernatant; finally, centrifuging the supernatant at a relative centrifugal force higher than the highest relative centrifugal force of the gradient centrifuging, then adding a standard phosphate buffer with a mass ratio of 1:8-1:10 to resuspend and precipitate, thereby obtaining the Caesalpinia minax lipid vesicle-like nanoparticles. The present application also provides the Caesalpinia minax lipid vesicle-like nanoparticles obtained by the method and the application of the Caesalpinia minax lipid vesicle-like nanoparticles in the treatment of ulcerative colitis. The present application overcomes the seasonal influence of the preparation of the existing tea lipid vesicle-like nanoparticles, greatly reduces the cost and controls the purity and quality, can solve the intestinal ecological imbalance problems such as mucosal epithelial repair and barrier homeostasis, has good safety and does not produce side effects, and is also a potential treatment for gastrointestinal disease treatment.